Public-private collaboration in clinical research during pregnancy, lactation, and childhood: Joint position statement of the early nutrition academy and the european society for pediatric gastroenterology, hepatology, and nutrition

Journal of Pediatric Gastroenterology and Nutrition

Volumn 58, Issue 4, 2014, Pages 525-530

  Koletzko, Berthold ^a   Benninga, Marc A ^b   Godfrey, Keith M ^c   Hornnes, Peter J ^d   Kolaček, Sanja ^e   Koletzko, Sibylle ^a   Lentze, Michael J ^f   Mader, Silke ^g   McAuliffe, Fionnuala M ^h   Oepkes, Dick ⁱ   Oddy, Wendy H ^j   Phillips, Alan ^k   Rzehak, Peter ^a   Socha, Piotr ^l   Szajewska, Hania ^m   Symonds, Michael E ⁿ   Taminiau, Jan ^b   Thapar, Nikhil ^o   Troncone, Riccardo ^p   Vandenplas, Yvan ^q   Veereman, Gigi ^q   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF ZAGREB   (Croatia)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g European Foundation for the Care of Newborn Infants   (Germany)

^h UNIVERSITY COLLEGE DUBLIN   (Ireland)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l Children's Memorial Health Institute   (United Kingdom)

^m MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁿ UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^o GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^p UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^q UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

biomedical research; clinical trials; drug industry; food industry; public private sector partnership; research ethics

Indexed keywords

ARTICLE; CHILDHOOD; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE POLICY; HUMAN; LACTATION; OFF LABEL DRUG USE; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROTOCOL COMPLIANCE; PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; STATISTICAL BIAS; SYSTEMATIC REVIEW (TOPIC); BREAST FEEDING; CHILD; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ETHICS; FEMALE; INFANT; MEDICAL RESEARCH; PRESCHOOL CHILD; STANDARDS; UNIVERSITY;

BIOMEDICAL RESEARCH; BREAST FEEDING; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; FEMALE; HUMANS; INFANT; PREGNANCY; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; UNIVERSITIES;

EID: 84897429663     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000284     Document Type: Article

References (46)

1. Olski TM, Lampus SF, Gherarducci G, et al. Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol 2011;67:245-52.
2. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Office of Research on Women's Health. Enrolling Pregnant Women: Issues in Clinical Research Bethesda, MD: National Institutes of Health; Office of Research on Women's Health; 2011.
3. Regulation (EC) No 1901/2006 of the EU Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, OJ L378/1-19 of 27.12.2006 (2006).
4. Mansi BA, Clark J, David FS, et al. Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective. Mayo Clin Proc 2012;87:424-9.
5. Krumholz HM, Ross JS. Relationships with the drug industry: more regulation, greater transparency. BMJ 2009;338:b211.
6. Brinjikji W, Kallmes DF. How everybody wins when playing by the rules: the benefits of investigator-initiated industry-sponsored clinical trials. Am J Neuroradiol 2011;32:427-9.
7. Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev (12):2012:MR000033.
8. Sen S, Prabhu M. Reporting bias in industry-supported medication trials presented at the American Psychiatric Association meeting. J Clin Psychopharmacol 2012;32:435.
9. Khan NA, Lombeida JI, Singh M, et al. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum 2012;64:2059-67.
10. Sinyor M, Schaffer A, Smart KA, et al. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-Analysis of randomized controlled trials. J Clin Psychiatry 2012;73:e277-87.
11. Steinbrook R, Kassirer JP. Data availability for industry sponsored trials: what should medical journals require? BMJ 2010;341:c5391.
12. Lesser LI, Ebbeling CB, Goozner M, et al. Relationship between funding source and conclusion among nutrition-related scientific articles. PLoS Med 2007;4:e5.
13. Bajpai V, Saraya A. Industry-sponsored clinical research. Natl Med J India 2011;24:300-2.
14. Angell M. Is academic medicine for sale? N Engl J Med 2000;342: 1516-8.
15. Bailey CS, Fehlings MG, Rampersaud YR, et al. Industry and evidence-based medicine: believable or conflicted? A systematic review of the surgical literature. Can J Surg 2011;54:321-6.
16. Fisher JA, Kalbaugh CA. United States private-sector physicians and pharmaceutical contract research: a qualitative study. PLoS Med 2012; 9:e1001271.
17. Nutrition Standing Committee. Guidelines for the Funding of Paediatric Research by Formula Companies. Sydney: The Royal Australasian College of Physicians; 2007.
18. Agostoni C, Braegger C, Decsi T, et al. Breast-feeding: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2009;49:112-25.
19. Koletzko B, Baker S, Cleghorn G, et al. Global standard for the composition of infant formula: recommendations of an ESPGHAN coordinated international expert group. J Pediatr Gastroenterol Nutr 2005;41:584-99.
20. ESPGHAN Committee on Nutrition Agostoni C, Aggett PJ, Agostini C, et al. The nutritional and safety assessment of breast milk substitutes and other dietary products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2001; 32: 256-8.
21. Koletzko B, Shamir R, Ashwell M. Quality and safety aspects of infant nutrition. Ann Nutr Metab 2012;60:179-84.
22. Koletzko B, Szajewska H, Ashwell M, et al. Documentation of functional and clinical effects of infant nutrition: setting the scene for COMMENT. Ann Nutr Metab 2012;60:222-32.
23. Koletzko B, Bhutta ZA, Cai W, et al. Compositional requirements of follow-up formula for use in infancy: recommendations of an international expert group coordinated by the Early Nutrition Academy. Ann Nutr Metab 2013;62:44-54.
24. Szajewska H. The role of systematic data reviews in safety assessment of infant nutrition. Ann Nutr Metab 2012;60:204-7.
25. Fewtrell MS. Clinical safety assessment of infant nutrition. Ann Nutr Metab 2012;60:200-3.
26. Shamir R. Thiamine deficient infant formula what happened, and what have we learned? Ann Nutr Metab 2012;60:185-7.
27. Ross JS, Gross CP, Krumholz HM. Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health 2012;102:72-80.
28. Rifai N, Plebani M, Wu A, et al. Full-disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors. Scand J Clin Lab Invest 2011; 71:177-8.
29. Lundh A, Krogsboll LT, Gotzsche PC. Sponsors' participation in conduct and reporting of industry trials: a descriptive study. Trials 2012;13:146.
30. COMMISSION DIRECTIVE 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for Good Clinical Practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such product. Official Journal of the European Union. 2005 (9.4.2005):L 91/13.
31. ICH Guidance E6: Good Clinical Practice: Consolidated Guideline. Ottawa: Health Canada; 2004.
32. World Health Organization. Guidelines for Good Clinical Practice (GCP) for trials on pharmaceutical products. WHO Technical Report Series. 1995; No. 850 (Annex 3).
33. Food and Drug Administration. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. Rockville MD: Drug Information Branch; 1996.
34. Food and Drug Administration Amendments Act of 2007. 21 USC §301 (2007). (2007).
35. Tse T, Williams RJ, Zarin DA. Reporting "basic results" in clinical-trials.gov. Chest 2009;136:295-303.
36. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013; 346:e7586.
37. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials. J Clin Epidemiol 2010;63:e1-37.
38. Campbell MK, Piaggio G, Elbourne DR, et al. CONSORT 2010 statement: extension to cluster randomized trials. BMJ 2012;345:e5661.
39. Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomized clinical trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008;5:e20.
40. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:a2390.
41. Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308:2594-604.
42. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
43. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-4.
44. Stroup DF, Berlin JA, Morton SC, et al. Meta-Analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-12.
45. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4:e296.
46. Graf C, Battisti WP, Bridges D, et al. Research methods & reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009;339:b5330.